Business Context and Reporting Period
NUR Macroprinters Ltd. (Nasdaq-SCM: NURM), a supplier of wide-format inkjet production printing systems, reported unaudited financial results for the first quarter ended March 31, 2004. The filing, submitted on April 29, 2004, marks the first quarter of operations following organizational changes and cost restructuring initiated in 2003.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Revenues | $18.5 million | $17.1 million |
| Gross Profit | $7.2 million (38.8% margin) | $5.7 million (33.4% margin) |
| Operating Income | $309,000 | ($1.1) million loss |
| Net Loss | ($0.98) million | ($1.46) million |
| Loss Per Share (Basic) | ($0.05) | ($0.09) |
| Cash and Equivalents | $13.4 million | $10.9 million (Dec 31, 2003) |
| Total Debt (Short & Long Term) | $45.8 million | $45.9 million (Dec 31, 2003) |
| Shareholders' Equity | $1.7 million | ($1.5) million (Dec 31, 2003) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8% year-over-year, driven by heightened interest in the company's technologically advanced product line.
- Profitability Turnaround: The company achieved operating income of $309,000, reversing an operating loss of $1.1 million in the prior year quarter. This improvement is attributed to the completion of organizational changes and the absence of prior-year inventory write-offs.
- Equity Position: Shareholders' equity turned positive ($1.7 million) from negative ($1.5 million) following a $3.0 million private financing round and the conversion of a $1.5 million standby loan.
- Expense Management: Selling expenses decreased significantly to $2.2 million from $3.0 million in Q1 2003, while R&D expenses increased slightly to $2.1 million.
Guidance, Outlook, and Risks
Full Year 2004 Guidance:
- Revenues: $80 to $82 million.
- Gross Margins: 41% to 43%.
- Operating Expenses: $29 to $30 million.
- Net Profit: $2.0 to $2.5 million ($0.07 to $0.10 per share).
Management Commentary: Management expects increased capacity to maintain future growth. New product introductions include the NUR Expedio (high-speed UV Curable printer), NUR Tempo L (mid-range flatbed), and Fresco 2. The company anticipates continued excitement at the DRUPA show in Germany.
Risks and Contingencies: Forward-looking statements are subject to risks including general economic conditions, decline in product demand, inability to timely develop new technologies, loss of market share, and competitive pricing pressure.
Investor Verification Checklist
- Verify the sustainability of the 38.8% gross margin and the ability to achieve the guided 41-43% range for the full year.
- Confirm the impact of the $3.0 million financing on the company's liquidity and debt covenants.
- Monitor the execution of new product launches (Expedio, Tempo L, Fresco 2) and their contribution to the revenue guidance.
- Assess the reduction in selling expenses and whether this trend can be maintained while scaling sales.
- Review the "Beneficial Conversion Feature" charge of $135,000 and its implications for future financing costs.